LCTX · Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc Is A Clinical-Stage Biotechnology Company Focused On The Development And Commercialization Of Novel Therapies For The Treatment Of Degenerative Diseases. The Company'S Pipeline Currently Includes: Opregen, Opc1, Resonance, Ilt1, Rnd1, Pnc1, And Lct-Con. Its Programs Are Based On Its Proprietary, In-House, Cell-Based Manufacturing Platform, Which It Call Alloscope (Allogeneic, Scalable, Consistent, Off-The-Shelf, Pluripotent Cell Engineering), And Supported By Its Associated Development, Formulation, Manufacturing, And Delivery Capabilities. The Alloscope Platform Is A Proprietary Differentiation And Production Modality From Which, A Single, Well-Characterized Pluripotent Cell Line Can Create A Stable Current Good Manufacturing Practice, Master Cell Bank.